Alnylam Pharmaceuticals ((ALNY)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Study Overview: Alnylam Pharmaceuticals is conducting a study titled A Randomized, Double-blind, Placebo-controlled Study, to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally Administered Single Ascending Doses of ALN-HTT02 in Adult Patients With Huntington’s Disease. The study aims to assess the safety and effectiveness of ALN-HTT02 in treating Huntington’s Disease, a significant step in addressing this debilitating condition.
Intervention/Treatment: The study tests ALN-HTT02, an experimental drug administered intrathecally, designed to evaluate its safety and pharmacological effects in patients with Huntington’s Disease.
Study Design: This Phase 1 trial is interventional, utilizing a randomized, parallel assignment model. It employs triple masking, meaning the participant, care provider, and investigator are unaware of the treatment allocation. The primary goal is treatment-focused.
Study Timeline: The study began on October 14, 2024, with a primary completion date yet to be announced. The latest update was submitted on July 15, 2025, indicating ongoing recruitment and progress.
Market Implications: The progress of this study could significantly impact Alnylam Pharmaceuticals’ stock, as positive results may enhance investor confidence and market position. The study’s outcome could also influence the competitive landscape in the biopharmaceutical industry, particularly in treatments for neurodegenerative diseases.
The study is currently ongoing, with further details available on the ClinicalTrials portal.